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Abstract 
The authors intend to present in this 
paper the most actual trends and 
perspectives in the challenging field of 
medulloblastoma multimodal treatment. 
The data collected from the medical 
literature and  augmented with personal 
experience, outline a scientifical and 
pragmatic conduct of medical thinking and 
action. 
The epidemiology, clinical presentation, 
neuroimaging modalities, pathology and 
therapy (surgical, XRT and chemotherapy) 
regardind this medical issue are thoroughly 
glanced and outlined. 
Epidemiology 
Medulloblastoma is a malignant and 
invasive embryonal tumor of the 
cerebellum, corresponding histologically to 
World Health Organization (WHO) grade 
IV, that has sometimes been referred to as 
an infratentorial primitive neuroectodermal 
tumor, or PNET. [21] 
Although medulloblastoma is the most 
common histologic type of malignant 
central nervous system (CNS) tumor in 
childhood (0 to 19 years), accounting for 
17.2% of these tumors, they account for 
only 0.7% of all malignant CNS tumors in 
adults (age ≥20). The incidence of this 
tumor steadily decreases with increasing age 
after a peak occurrence at age 6. It is 
estimated that only 29% of 
medulloblastomas occur in patients age 20 
or older. This tumor rarely occurs after the 
age of 50. Sixtytwo percent of patients are 
male (61% age <20 and 63% age≥20). 
Important clinical features 
The clinical presentation of posterior 
fossa tumors is similar in adults and 
children, and many signs and symptoms are 
related to hydrocephalus caused by 
obstruction of cerebrospinal fluid (CSF) 
flow by the tumor.  
Early in the course of disease, complaints 
of nonspecific headache, fatigue, slight 
imbalance, and personality changes may 
occur. As the disease progresses, signs and 
symptoms of increased intracranial pressure 
predominate, especially headache. These 
headaches are usually present on awakening 
in the morning and improve or resolve after 
rising and as the day progresses. Headaches 
may become persistent if the tumor is not 
diagnosed and treated. Nausea and 
vomiting are also common. Sixth cranial 
nerve palsies and diplopia, caused by 
increased intracranial pressure, are not 
uncommon.  
Focal neurologic deficits caused by 
pressure on or infiltration of the brainstem, 
cranial nerves, or cerebellar structures also 
occur. 
Dizziness or other cerebellar 
dysfunction occurs in most patients, and 
the pattern of deficits is related to the 
location of tumor in the posterior fossa. 
Lesions occurring in the midline are likely 
 
 
 
292          A.V. Ciurea, Claudiu Palade          Medulloblastoma – an overview 
 
 
 
to cause truncal and gait ataxia, whereas 
limb ataxia is more common in lesions 
involving the lateral cerebellar hemispheres. 
Other focal neurologic deficits such as 
hemiparesis, hearing loss, and seventh 
cranial nerve palsies occur less often. 
Seizures are rarely seen in children or 
adults with PF tumors unless extension into 
the supratentorial cortex occurs.  
Alterations of consciousness may occur 
late in the course of the disease. 
Hemorrhage into the PF mass may cause 
acute loss of consciousness and coma. 
Neuroimaging 
Because of its exquisite contrast 
resolution, MRI is the imaging modality of 
choice in the preoperative work-up for 
infratentorial tumors and for the evaluation 
of leptomeningeal metastasis. Once 
medulloblastoma is suspected on imaging 
or confirmed cytologically or pathologically, 
MRI of the brain and entire spine before 
and after administration of gadolinium 
contrast becomes necessary. 
The goal of this imaging is to determine 
whether there are demonstrable metastases 
in the craniospinal axis because of the 
significant impact these metastases have on 
management and prognosis.[2,28,38] 
 
 
Figure 1 Preoperative MRI aspect –axial incidence 
(personal case) 
 
Figure 2 Preoperative MRI aspect – sagital incidence 
(personal case) 
 
It is estimated that approximately one 
half of adult patients with medulloblastoma 
have their tumors originate peripherally in 
the cerebellum (paramedian and lateral 
locations). On rare occasions, a 
medulloblastoma presents as an exclusively 
extra-axial mass in the cerebellopontine 
angle and may be mistaken for a 
meningioma or vestibular schwannoma on 
computed tomography (CT) and MRI 
scans.[2,38]  
Adult medulloblastoma is typically 
heterogeneous on CT and can appear 
hypodense or hyperdense to gray matter 
and have variable patterns of 
enhancement.[2,6] The more common 
peripheral tumors are poorly enhanced with 
contrast, whereas the less common vermian 
central tumors tend to be intensely 
enhanced with contrast. On MRI, tumors 
show hypointense signal on T1 - and 
hyperintense signal on T2 - weighted 
images. Contrast-enhanced T1 sequences 
best demonstrate the heterogeneity of these 
tumors. Small cysts are commonly 
encountered in the peripheral tumors, 
whereas a predominantly cystic 
medulloblastoma is rare.[6,34,38] 
Melanotic medulloblastoma is a rare 
form of medulloblastoma that can 
potentially demonstrate high T1 signal on 
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the unenhanced T1 sequences.[22,60] This 
high signal can suggest or be confused with 
hemorrhage.  
A rare entity in the adult literature, 
“lipidized” or “lipomatous” 
medulloblastoma has been provisionally 
reclassified by WHO as cerebellar 
liponeurocytoma (9506/1) and can also 
demonstrate high signal on unenhanced T1 
sequences. MRI of the brain and spine is 
useful in assessing response to treatment, 
stability, tumor progression, and metastatic 
disease. MRI of the entire spine with and 
without gadolinium contrast enhancement 
has become the study of choice for 
evaluating drop metastases. 
Pathological aspects 
The gross appearance and histology of 
medulloblastoma occurring in adults 
overlap substantially with the features of 
pediatric medulloblastoma. The histology 
includes the five principal patterns: 
1) undifferentiated or classic medullo-
blastoma,  
2) desmoplastic nodular medullo-
blastoma,  
3) medulloblastoma with neuroblastic or 
neuronal differentiation, 
4) large cell or anaplastic medullo-
blastoma,  
5) medulloblastoma with glial 
differentiation.[7,21]  
The other variant forms such as: 
6) medullomyoblastoma and  
7) melanotic medulloblastoma are rare 
in the adult population, [44,57] and they 
are the forms containing more 
heterogeneous differentiation. 
Undifferentiated or “classic” 
medulloblastoma, consisting of patternless 
masses of monotonous small cells, 
comprises the majority of 
medulloblastomas in both adult and 
pediatric groups. 
 
Figure 3 Microscopic aspect of a medulloblastoma  
specimen (HE stain) 
 
Evidence of neuronal differentiation by 
hematoxylin and eosin (H&E) staining in 
some cases includes the formation of 
neuroblastic rosettes and, occasionally, the 
presence of ganglion cells. Despite the 
common lack of evidence of differentiation 
by routine H&E staining, evidence of 
neuronal differentiation may be 
demonstrable by immunohistochemical 
staining for synaptophysin or other 
neuronal markers or by the electron 
microscopic demonstration of neurites, 
synaptic structures, or neurosecretory 
granules.  
The findings of necrosis, apoptosis, 
calcification, infiltrative behavior, 
intratumoral hemorrhage, and tumor 
extension into the overlying leptomeninges 
occur in both pediatric and adult cases. 
The nodular or desmoplastic variety, 
defined by the presence of prominent 
nodules or “pale islands” of tumor of lower 
cellularity in a background of collagen-rich, 
highly proliferative tumor, occurs more 
often in the older 
population.[1,23,33,45,56] 
A rare variant medulloblastoma with 
extensive nodularity and neuronal 
differentiation associated with a more 
favorable prognosis is more common in the 
pediatric population.[17,24] 
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Medulloblastoma with neuroblastic or 
neuronal differentiation  characterized by 
extensive nodularity and differentiation 
toward neurocytes or ganglion cells and 
referred to by some authors as “cerebellar 
neuroblastoma,” is an uncommon variant 
and occurs primarily in infants and very 
young children.  
Large cell or anaplastic medulloblastoma, 
characterized by populations of larger, more 
pleomorphic tumor cells than those in 
classic medulloblastoma, is also an 
uncommon variant occurring 
predominantly in the pediatric population 
and is often associated with an unfavorable 
outcome. [16,25] 
Glial rather than neuronal differentiation 
in medulloblastoma has been reported in 
up to one third of cases of medulloblastoma 
occurring in older individuals. Mature glial 
cells, identified by the presence of 
eosinophilic cytoplasm and cell processes, 
may be difficult to identify in H&E-stained 
sections. By immunohistochemical staining 
for glial fibrillary acidic protein (GFAP), 
immunoreactive fibrillated cells can be 
identified in most pediatric [11] and adult 
medulloblastomas, typically in a 
perivascular location or at the periphery of 
the tumor. Although such cells have 
commonly been considered entrapped 
reactive astrocytes rather than tumor cells, 
similar cells have been observed in 
metastatic medulloblastoma in nonbrain 
sites, suggesting that they are actually tumor 
cells. 
Glial differentiation in tumor cells, 
usually defined by the finding of glial 
fibrillary acidic protein-immunoreactivity 
in the perikaryon or short cell processes of 
cells with distinctively neoplastic nuclear 
features, has been described in a small 
percentage of medulloblastomas, 
particularly in the adult population. GFAP-
immunoreactive cells have also been noted 
within the nodules and in the internodular 
tumor cell population of desmoplastic 
nodular medulloblastomas. Studies 
investigating the prognostic significance of 
glial differentiation have yielded 
contradictory results.[11,29,35] 
In the pediatric population, suggestions 
of correlations between genetic markers and 
prognosis such as cytogenetic studies of 
chromosome 17 and others, p53 
overexpression, studies of ErbB2 receptors, 
high TRKC receptor expression, 
amplification of MYC, and abnormalities in 
the sonic hedgehog (SHH)–PTCH 
pathway have been noted, with the best 
correlations occurring in the large cell–
anaplastic variant.[17,42,65] 
In adult medulloblastoma, a recent study 
correlated overexpression of MDM2 with 
shorter survival. [27,28] 
More recently, cDNA-based gene-
expression profiling has demonstrated that 
medulloblastomas are distinct from 
primitive neuroectodermal tumors and that 
the “classic” and desmoplastic subtypes are 
distinct.[54] These studies confirmed 
earlier observations about high TRKC 
receptor expression and amplification of 
MYC. These studies have also strongly 
supported the hypothesis that 
medulloblastomas are derived from 
cerebellar granular cells through the 
activation of the SHH pathway and 
suggested various novel prognostic markers 
related to SHH pathway activation. 
However, more extensive investigation will 
need to be carried out to verify the utility of 
the various genetic and molecular markers 
in assessing prognosis, especially in the 
forms of medulloblastoma more commonly 
encountered in the adult population such as 
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desmoplastic nodular medulloblastoma. 
Furthermore, a parallel between pediatric 
and adult tumors cannot be assumed. 
Tumor staging 
The Chang staging system , which was 
published in 1969, evaluates tumor size, 
local extension, and the presence or absence 
of metastases.[10] The tumor (T) staging 
portion of the staging system may no longer 
have the same prognostic value that it once 
had. Several pediatric studies have shown 
that the amount of residual disease, age, and 
M stage are more predictive of outcome 
than T stage.[39,66] 
It was initially based on the surgeon’s 
intraoperative observations; however, in the 
modern era of neuroimaging, preoperative 
and postoperative scans provide similar if 
not better information.  
Chang Staging System for Metastasis 
(M staging portion) 
Stage Definition 
M0 - No evidence of gross subarachnoid 
or hematogenous metastasis 
M1 - Microscopic tumor cells found in 
cerebrospinal fluid 
M2 - Gross nodular seedings 
demonstrated in the cerebellar, cerebral 
subarachnoid space, or in the third or lateral 
ventricles 
M3 - Gross nodular seeding in spinal 
subarachnoid space 
M4 - Extraneuroaxial metastasis 
 
The Chang metastasis (M) stage (M0 
denotes local disease only, M1 denotes 
positive CSF cytology, M2 denotes tumor 
present beyond the primary site but within 
the brain, M3 denotes gross nodular 
seeding in the spinal subarachnoid space, 
and M4 denotes extracranial spread) has 
consistently been related to outcome in 
pediatric studies, although this is less clear 
in adult series. 
Evaluation for the purpose of staging 
includes preoperative MRI scans of the 
cranial vault and entire spine. CSF 
sampling should be performed before 
surgery or 10 to 14 days postoperatively to 
avoid a false positive related to surgery. 
Postoperative MRI scans of the brain 
should be obtained within 24 to 48 hours 
after resection to minimize postoperative 
imaging changes and accurately evaluate the 
extent of resection. If a preoperative MRI 
scan of the spine was not performed, it 
should be performed 2 weeks after surgical 
resection to allow for resolution of 
postoperative blood and protein artifacts 
that may be misinterpreted as metastatic 
tumor. 
Over the past 10 to 15 years, sequential 
studies carried out by the Children’s 
Cancer Group (CCG) and the Pediatric 
Oncology Group (POG)[18,19,49,51] have 
revealed two risk categories defined by age, 
extent of surgical resection, and M stage. 
Patients are considered to be average or 
standard risk if they are older than 3 years, 
have no more than 1.5 cm2 of residual 
tumor after surgical resection, and have no 
CSF or spinal involvement (M0).(66) All 
other pediatric medulloblastoma patients 
are considered to be poor or high risk. 
Although recent data suggest that a 
histologic variant showing moderate to 
severe anaplasia may have an adverse 
prognosis in pediatric tumors,16 this and 
other possible genetic and histopathologic 
prognostic variables have not yet been used 
in prospective risk categorization, and need 
to be verified in other 
studies.[17,27,28,42,65] 
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Surgical treatment 
Surgery plays an integral and important 
role in the management of adults with 
medulloblastoma. The goals of surgical 
therapy are threefold: histologic diagnosis, 
maximal safe tumor resection, and 
restoration of patency of CSF pathways. 
Because medulloblastomas commonly 
present with some degree of hydrocephalus, 
the first surgical decision often pertains to 
management of this condition. Tumor 
resection alleviates hydrocephalus in up to 
90% of patients in most modern series,[63] 
and avoids shunt-related complications 
such as upward herniation of the brainstem, 
intratumoral hemorrhage, and CSF 
dissemination. 
Thus prompt, definitive surgical 
resection with use of steroids to control 
edema is preferred to a staged approach of 
shunting followed by resection. If steroids 
fail or urgent ventricular drainage is 
required, a nondominant ventriculostomy 
is preferred over a shunt, because it allows 
more precise control of intracranial 
pressure and drainage. Care should be taken 
to measure opening pressure and drain 
slowly at 20 cm of CSF or higher, and 
resection should be accomplished 
promptly. 
Numerous studies have demonstrated 
the relationship between extent of resection 
and prognosis [41]; thus optimization of 
the surgical procedure is critical. This is 
achieved in part by meticulous preoperative 
preparation and by using stereotactic 
computer-aided navigation (CAN) tools, 
intraoperative ultrasound, and in some 
cases, brainstem evoked-potential 
monitoring. 
 
Figure 4 Patient Positioning (Prone position) – 
routinely used by the senior author 
 
Surgery is more often performed with 
patients prone to avoid the risk of air 
embolism and subdural hematoma 
associated with sitting. The patient is 
managed preoperatively with antibiotics, 
corticosteroids, mannitol, and moderate 
hyperventilation. 
A ventriculostomy is usually performed 
at the time of surgery if it has not already 
been performed and is managed as noted 
previously.  
After a generous craniotomy or 
craniectomy centered over the tumor, the 
cisterna magna is opened to drain CSF. 
Although invasive, the tumor usually is 
surrounded by a pseudocapsule facilitating 
identification and removal from the 
surrounding brain. CAN and ultrasound 
are also helpful in this regard.  
Using microsurgical techniques, the 
tumor is internally debulked using an 
ultrasonic aspirator and a self-retaining 
retractor to minimize cerebellar retraction. 
The surgeon must anticipate the location of 
critical structures such as the posterior 
inferior cerebellar artery, inferior vermian 
veins, cranial nerves (in the case of laterally 
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placed tumors), the dentate nuclei, the 
cerebellar peduncles, and the floor of the 
fourth ventricle. Often, the tumor can be 
gently peeled from these structures without 
damaging the pial membrane. The surgeon 
places cottonoids along the cisterna magna 
and along the roof and floor of the fourth 
ventricle to prevent iatrogenic 
dissemination of tumor along CSF 
pathways as these structures are exposed.  
Invasive tumor is aggressively resected 
from the cerebellum and, if required, a 
single cerebellar peduncle. However, 
aggressive resection of tumor invading the 
floor of the fourth ventricle or the second 
cerebellar peduncle is avoided to reduce 
unacceptable postoperative morbidity. 
After as complete a gross resection 
consistent with good neurologic function 
has been achieved, the resection cavity is 
reinspected using microscopic 
magnification, CAN, and ultrasound to 
identify and then resect any residual tumor, 
cerebellar hematoma, or retraction injury. 
Meticulous hemostasis minimizes 
postoperative nausea, vomiting, and 
hydrocephalus. 
A watertight closure of the dura is 
performed using tisseal or fibrin glue to 
avoid CSF leak, pseudomeningocele, and 
chemical meningitis. Postoperatively, the 
ventriculostomy is drained until the blood 
clears, and then the patient weaned from 
ventricular drainage if possible.  
Postoperative MRI with and without 
contrast is done within 48 hours 
postoperatively, both as a baseline and to 
assess extent of resection. MRI of the spinal 
axis should be performed approximately 2 
weeks after surgery if it has not been done 
preoperatively. (Figure 5-personal case) 
 
Figure 5 (Postoperative aspect- CT scan same 
personal case shown in Fig 1&2) 
 
If significant resectable residual 
neoplasm is seen or the patient requires a 
ventriculoperitoneal shunt, prompt 
reoperation is indicated to avoid delay of 
postoperative radiation therapy and 
chemotherapy. 
Operative mortality should be well 
under 1%; morbidity is 5% to 10% in most 
series.[41]  
Most common complications are 
transient, including ataxia, nystagmus, and 
dysmetria. Cranial nerve palsies are related 
to manipulation along the floor of the 
fourth ventricle.  
Cerebellar mutism may also be induced 
by damage to the dentate nuclei. It is 
advisable to wait 10 to 14 days after surgery 
before beginning radiation therapy to 
ensure adequate wound healing and 
minimize the possibility of wound 
dehiscence. 
Radiation therapy 
When radiation therapy is used in newly 
diagnosed patients, the standard dose 
delivered to the craniospinal axis is 35 to 36 
Gy if patients have no evidence of neuraxis 
dissemination (M0). The PF is then 
boosted for an additional 18 to 20 Gy so 
that the total dose to the PF is 
approximately 54 to 56 Gy. If CSF cytology 
is positive (M1), the recommended dose to 
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the CSA according to the pediatric 
experience is still only 36 Gy. If nodular 
disease in the subarachnoid space (M2 or 
M3) is present, a boost is delivered 
immediately following CSI to the site of the 
original metastatic disease (M2 to M3) up 
to a total dose of 45 Gy. The fractionation 
scheme used most often is 1.8 Gy daily, 5 
days per week. 
The current standard therapy is to boost 
the entire PF to a total dose of 54 to 55.8 
Gy at a fractionation of 1.8 Gy per day 
using high-energy photons (x-rays). There 
are no convincing data that administering 
higher doses to the PF by conventional 
fractionation or hyperfractionated treatment 
schedules improves outcomes,[55] 
although boosting residual disease with a 
stereotactic radiosurgical boost has shown 
promise in a limited number of 
patients.[52,64] 
The duration of radiation therapy may 
also influence outcomes. Taylor et al[61] 
showed a statistically significant reduction 
in overall survival and EFS if the time from 
the first radiation treatment to the last 
radiation treatment was more than 50 days. 
In this study, there was no difference in the 
mean or median duration of radiation 
therapy between those patients treated with 
radiation therapy alone and those treated 
with chemotherapy followed by irradiation. 
It is advisable to complete radiation therapy 
without breaks. 
Complications associated with radiation 
therapy can be divided into two time 
frames: acute effects occurring during or 
shortly after treatment, and late effects 
occurring months to years after completion 
of treatment.  
Acute side effects in adults are usually 
more pronounced than in children and 
consist of nausea, vomiting, fatigue, 
alopecia, skin erythema, significant bone 
marrow suppression, soreness in the back 
of the throat with resultant dysphagia, 
transient loss of taste, transient xerostomia, 
and occasionally wound dehiscence (usually 
when there is not an adequate 10- to 14-day 
interval between surgery and initiation of 
radiation therapy). Late effects are generally 
less prominent in adults than in children 
and include potential pituitary dysfunction, 
possible infertility, effects on cognition, and 
possible induction of second malignancies. 
Although the neurocognitive effects in 
treated adults have not been studied as 
extensively as in children, there are data to 
suggest that cranial doses of 30 to 36 Gy 
may have an impact on cognitive function 
in survivors, especially on memory, 
reasoning, visualspatial ability, and 
arithmetic calculation skills.[40] 
Chemotherapy 
The usefulness of chemotherapy has 
been established in the pediatric 
medulloblastoma population. However, for 
adults with medulloblastoma, the role of 
chemotherapy is not yet established. The 
most commonly used regimen is the Packer 
regimen, which consists of weekly 
vincristine during CSI and eight cycles of 
CCNU, cisplatin, and vincristine (CCV) 
after CSI for children with 
medulloblastoma. This has become the 
standard against which all other 
chemotherapy regimens are measured.[49] 
There has not been a preradiation 
chemotherapy combination used in a 
randomized trial that has shown better 
efficacy as measured by overall survival or 
progression-free survival, although a 
recently reported study by Taylor et al 
describes EFS at 5 years that is comparable. 
[61] 
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The most notable dose-limiting side 
effects of this CCV-chemotherapy 
combination are peripheral neuropathy, 
hearing loss, renal insufficiency, and 
myelosuppression. As with most 
chemotherapy regimens, occasional patients 
succumb to overwhelming infection.  
Less serious side effects include nausea, 
vomiting, constipation, obstipation, and 
elevated transaminases. Hundreds of 
children have been treated with this 
combination, but there is little in the 
literature to describe the tolerance that 
adults have to the same combination. 
Whereas the thrust of recent pediatric trials 
has been to add chemotherapy to decrease 
the dose of craniospinal axis radiation and 
thereby decrease the harmful effects of 
radiation on neurocognitive and endocrine 
function such as low full-scale intelligence 
quotients (IQs) and short stature, there has 
not been a comparable effort in treating 
adults for several reasons. These reasons 
include the fact that there is an approximate 
60% 5-year progression-free survival rate 
with surgery and CSI alone [8] a belief that 
there is less harm to giving standard 
radiation doses to adults than children, and 
a less convincing case for a survival benefit 
to receiving chemotherapy as part of initial 
therapy. As a result, there is a perception 
among many clinicians that one can safely 
rely more on radiation and omit 
chemotherapy. However, there has been 
little formal investigation of 
neuropsychologic sequelae in adults who 
are long-term survivors of 
medulloblastoma.  
In the largest series of adult patients 
reported to date, a retrospective analysis 
involving 156 patients treated at 13 
institutions in France, Carrie et al 
concluded that 5- and 10-year EFS rates of 
61% and 48%, respectively, were similar to 
those observed in children.  
Their ultimate conclusion was that 
radiation therapy at the usual dose without 
chemotherapy should be considered the 
standard postoperative treatment in adults 
with medulloblastoma. 
Greenberg et al [30] retrospectively 
analyzed a group of adults diagnosed 
between 1991 and 1997 who were treated at 
one of three institutions with 
chemotherapy consisting of the Packer 
regimen51 or a POG protocol consisting of 
preradiation chemotherapy with cycles of 
cisplatin and etoposide alternating with 
cyclophosphamide and vincristine15 
followed by CSI. 
There is agreement among those who 
have written about the management and 
treatment of medulloblastoma in adults that 
patients should have maximal safe tumor 
resection followed by CSI. The role of and 
type of chemotherapy that should be 
employed and when it should be used 
remains less clear. 
Most neuro-oncologists would agree 
that patients with poor-risk 
medulloblastoma should also be treated 
with chemotherapy as part of initial 
therapy, but there is not agreement about 
its use in average-risk patients. There is a 
suggestion that combinations of 
cyclophosphamide or ifosfamide plus 
carboplatin or cisplatin plus vincristine with 
or without etoposide may be as effective 
and less toxic to adults than the Packer 
CCV regimen. Clinical trials in the adult 
population would help clarify the role of 
chemotherapy, especially in patients with 
average-risk disease. 
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Outcome 
The ability to categorize patients by risk 
factors has led to specific tailoring of 
treatment for the pediatric population,[66] 
and it is against these results that adult 
studies need to be compared.  
Since the initial encouraging reports 
describing the use of combination 
chemotherapy and reduced-dose radiation 
therapy by Packer et al [51] in the early 
1990s, this approach has become the 
standard of care at most pediatric 
institutions. In 1999, Packer et al [49] 
reported the results of a CCG study using a 
reduced craniospinal dose (23.4 Gy) of 
irradiation given with weekly vincristine 
followed by chemotherapy consisting of 
CCNU, vincristine, and cisplatin for eight 
cycles following CSI for average-risk 
patients between the ages of 3 and 10 years. 
The total dose to the PF remained at 55.8 
Gy. The progression-free survival rates 
were 86% at 3 years and 79% at 5 years, 
which were more favorable than historical 
comparisons from previous CCG or POG 
studies. In 2003, Taylor et al [61] reported 
the results of a European prospective 
randomized trial in which pediatric patients 
with M0 and M1 disease were randomized 
to radiation therapy alone versus 
preradiation therapy chemotherapy with 
vincristine, etoposide, carboplatin, and 
cyclophosphamide. 
The radiation therapy consisted of 35 Gy 
CSI in 1.67 Gy daily fractions followed by a 
PF boost of 20 Gy for a total PF dose of 55 
Gy in both treatment arms. The EFS was 
superior in the patients who received 
preradiation chemotherapy, with EFS at 5 
years of 74% versus 59.8% in the patients 
who received radiation therapy alone. 
Improvements in imaging modalities, 
surgical techniques, and the precision of 
radiation therapy delivery, as well as the 
addition of systemic chemotherapy over the 
past 2 decades, have contributed to the 
increased overall survival in pediatric series. 
It is more difficult to assess improvement in 
the outcome of adults with 
medulloblastoma because of the paucity of 
patients and lack of prospective or 
randomized adult trials.  
It is most likely that the improvement in 
survival of these groups is related most to 
the improvements in surgical techniques, 
radiation therapy, and imaging and probably 
less to the improvements in the addition of 
chemotherapy, at least in the adult 
population. 
Conclusions 
Medulloblastoma represent an important 
therapeutical problem of pediatric 
neurosurgical pathology. 
MRI of the head and spine represent an 
efficient and early diagnostic procedure. 
There is a high probability of CSF 
dissemination in medulloblastoma natural 
history. 
The autors emphasize the role of the 
multimodal therapy. 
Severe prognosis is expected in this 
condition - overall survival ranges from 
25% to 84% at 5 years with 10-year survival 
rates ranging from 35.6% to 51%. 
[44,45,46] 
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